StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Clinical TrialApr 21, 2026, 04:07 PM

Inhibrx Ozekibart Shows 20% ORR in Colorectal Cancer Study

AI Summary

Inhibrx Biosciences announced updated interim data from its Phase 1/2 study of ozekibart (INBRX-109) in combination with FOLFIRI for locally advanced or metastatic colorectal cancer. The study showed a 20% Objective Response Rate (ORR) in 45 evaluable patients, demonstrating a compelling signal of activity. This data is significant as the patient population was heavily pretreated, with 70% receiving ozekibart as a fourth-line therapy and 80% having progressed on prior irinotecan-based regimens.

Key Highlights

  • Ozekibart (INBRX-109) Phase 1/2 study in colorectal cancer.
  • Objective Response Rate (ORR) of 20% in 45 evaluable patients.
  • Approximately 70% of patients received ozekibart as fourth-line therapy.
  • 80% of patients previously progressed on irinotecan-based regimens.